EMPOWERING PATIENTS THROUGH REVELATIONARY SCIENCE

## **Company Overview**

Dr. Neal Walker President and CEO January 2019



### Cautionary Note Regarding Forward-Looking Statements

Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "believe", "expect", "may", "plan," "potential," "will," and similar expressions, and are based on Aclaris' current beliefs and expectations. These forward-looking statements include expectations regarding Aclaris' development programs in skin and hair conditions, the clinical development of JAK inhibitors, and the benefits and synergies of Aclaris' acquisition of RHOFADE. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Aclaris' reliance on third parties over which it may not always have full control, and other risks and uncertainties that are described in the Risk Factors section of Aclaris' Annual Report on Form 10-K for the year ended December 31, 2017, Aclaris' Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 and other filings Aclaris makes with the U.S. Securities and Exchange Commission from time to time. These documents are available under the "SEC filings" section of the Investors page of Aclaris' website at http://www.aclaristx.com. Any forward-looking statements speak only as of the date of this presentation and are based on information available to Aclaris as of the date of this presentation, and Aclaris assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise

This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.



### Our Corporate Strategy: Building a Fully-Integrated Biopharmaceutical Company



APPLY UNIQUE LEADERSHIP INSIGHTS

- 250+ years of relevant experience in dermatology
- 300+ years of drug discovery experience in immunology
- Key leadership with track record of executing across multiple development and commercial stage companies



ACCELERATE NOVEL, DIVERSE PIPELINE

- A-101
  - A-101 45%
    - Common Warts
    - Dosed first patient in phase
       3 trials in 9/2018
- Immunology Portfolio
  - ATI-501/ATI-502 (JAK 1/3 Inhibitors)
    - Alopecia Areata, Vitiligo
  - ATI-450 (MK-2 inhibitor)
    - RA, Psoriasis, CAPS, HS, PG
  - ATI-1777 (Soft JAK inhibitor)
    - Atopic Derm, Alopecia Areata, Vitiligo
  - ITK/JAK3 (Soft topical inhibitor)
    - Psoriasis, Inflammatory Dermatoses



ASSET AND COMMERCIAL STRATEGY

- Time and capital efficient
- Commercialize ESKATA<sup>®</sup> (hydrogen peroxide) topical solution, 40% (w/w) as a self-pay treatment administered in-office.
- Focus on large, underserved market segments in dermatology and inflammation.



### Pipeline

Program	Indication(s)	Preclinical	Phase 1	Phase 2	Pha
A-101(45%) Topical	Common Warts				
ATI-502 JAK1/JAK3 Inhibitor Topical	Alopecia Areata				
	Vitiligo				
	Androgenetic Alopecia (exploratory)				
	Atopic Dermatitis (exploratory)				
ATI-501 JAK1/JAK3 Inhibitor Oral	Alopecia Areata				
ATI-450 MK2 Pathway Inhibitor Oral	RA, Psoriasis, Hidradenitis Suppurativa, CAPS, Pyoderma Gangrenosum, Other				
ATI-1777 JAK1/JAK3 Inhibitor Soft Topical	Atopic dermatitis, Vitiligo, Alopecia Areata				
ITK/JAK3 Inhibitor Soft Topical	Psoriasis, Inflammatory Dermatoses				
ITK/JAK3 Inhibitor Oral	Psoriasis, Inflammatory Dermatoses				
MK2 Pathway Inhibitor Oral	Oncology				
ITK/JAK3 Inhibitor Oral, gut-restricted	Ulcerative colitis / Crohn's disease				



### **Conditions with Significant Treatment Gaps**

### SEBORRHEIC KERATOSIS (SK)

#### 83+MM<sup>\*</sup> people<sup>1</sup>

ESKATA<sup>®</sup> first FDA-approved topical treatment for raised SK Includes all types of SKs

#### VERRUCA VULGARIS (COMMON WARTS)



#### 22+MM people

in U.S.<sup>2</sup>; current treatments show only modest therapeutic effect and have significant limitations<sup>3,4</sup>

#### VITILIGO

## 1-2% global population impacted<sup>8</sup>;



no FDA-approved medication to repigment the skin<sup>9</sup>

#### ALOPECIA AREATA (AA)

#### 6.8+MM people

in U.S. have had or will develop AA<sup>5</sup>; current available Rx treatment options used off label and have significant limitations

#### ANDROGENETIC ALOPECIA (MALE / FEMALE PATTERN HAIR LOSS) 35MM men and 21MM women



in U.S. suffered from hair loss in 2012<sup>6,7</sup>; demand for treatment is high

<sup>1</sup>Bickers et al. The Burden of Skin Disease. J Am Acad Dermatology. 2006;55:490-500.<sup>2</sup>Nguyen et al. Laser Treatment of Nongenital Verrucae A Systematic Review. JAMA Dermatology. 2016;152(9):1025-1033.<sup>3</sup>Kwok et al. Topical treatments for cutaneous warts (Review). Cochrane Database of Systematic Reviews.2012. Art. No.: CD001781.<sup>4</sup>Mulhem et al. Treatment of Nongenital Cutaneous Warts. American Family Physician. 84:3, 2011; 288-293.<sup>5</sup>National Alopecia Areata Foundation. https://www.naaf.org/alopecia-areata. Last accessed July 2, 2019.<sup>6</sup>International Society of Hair Restoration Surgery. http://www.ishrs.org/node/3094. Last accessed July 24, 2019.<sup>7</sup>Herskovitz, I, et al. Female Pattern Hair Loss. International Journal of Endocrinology and Metabolism. 2013 Oct; 11(4): e9860. <sup>8</sup>Fitzpatrick T, et al. http://www.avrf.org/facts/frequently-asked-questions.html. Last accessed July 24, 2019.<sup>9</sup>The Vitiligo Therapeutics Market is Expected to Show Moderate Growth up to 2019. 2012. https://www.asdreports.com/news-217/vitiligo-therapeutics-market-expected-show-moderategrowth-up-2019. Last accessed July 24, 2019



### RHOFADE<sup>®</sup> (oxymetazoline HCl) cream, 1%





### RHOFADE



The National Rosacea Society (NRS) estimates that approximately 16 million Americans are affected by rosacea.<sup>1</sup> Persistent facial redness is cited as the most common sign of rosacea, and may resemble a flushing or sunburn that does not go away.<sup>2</sup> Typical triggers include sun exposure, stress, weather, food, exercise and/or products.<sup>3</sup> In an NRS survey, 65% of rosacea patients surveyed said their symptoms first appeared between 30-60 years of age.<sup>4</sup>

1 National Rosacea Society, <a href="https://www.rosacea.org/rr/2010/winter/article\_1.php">https://www.rosacea.org/patients/allaboutrosacea.php</a>, 2 National Rosacea Society, <a href="https://www.rosacea.org/weblog/risks\_answer\_whp">https://www.rosacea.org/patients/allaboutrosacea.php</a>, 2 National Rosacea Society, <a href="https://www.rosacea.org/weblog/risks\_answer\_whp">https://www.rosacea.org/patients/allaboutrosacea.php</a>, 2 National Rosacea Society, <a href="https://www.rosacea.org/weblog/risks\_answer\_whp">https://www.rosacea.org/weblog/risks\_answer\_whp</a>, 4 National Rosacea Society, <a href="https://www.rosacea.org/weblog/risks\_answer

Last accessed on September 30, 2018



### **RHOFADE** Rationale



- Understanding of RHOFADE by management team due to role in development
- Expected synergies by leveraging current infrastructure and sales force in the U.S.
- Significant overlap (~70%) in existing call points for current field force who will detail both ESKATA and RHOFADE
- Intellectual property includes multiple patents, the last of which expires in 2035
- Deal is expected to be accretive to Aclaris' earnings beginning in the fourth quarter of 2019
- Approved indication for the treatment of persistent facial erythema (redness) associated with rosacea in adults
- Establishes a presence in medical dermatology in advance of A-101 45% for the treatment of common warts, if approved
- Opportunity to acquire a recently launched, but currently non-promoted asset in the rosacea market
- Allergan has agreed to provide financial, distribution, and commercial support to Aclaris for a smooth transition



### **RHOFADE Deal and Oxford Debt Terms**

#### Acquisition:

- Asset Purchase for the Worldwide RHOFADE® (oxymetazoline HCI) cream, 1% product rights and additional IP
- RHOFADE trailing twelve-month (TTM) net sales of \$17.5 million through June 30, 2018

#### **Consideration to Allergan:**

- \$65M upfront
- Royalties payable to Allergan:
  - 10% on RHOFADE net sales up to \$100m
  - 12.5% on RHOFADE net sales between \$100m \$150m
  - 15% on RHOFADE net sales over \$150m
- \$5m milestone due to Allergan for the achievement of a specified development milestone for potential development of an additional dermatology product
- Assumption of payment obligations to Aspect and Vicept
  - Aspect
    - One-time upon achievement of net revs in annual period of \$100m
    - Royalties payable at 4.5% on RHOFADE net sales up to \$100m.
  - Vicept
    - One-time upon achievement of net revs in 12mo period in excess \$250m, \$350m and \$500m

#### **Debt Terms:**

- \$65M total available for draw through Term Loan with Oxford Finance
- \$30M borrowed on October 31, 2019
- \$35M balance available from closing of RHOFADE acquisition until March 31, 2019
- Key Terms on new Term Loan
  - Interest only for 36 months, followed by 24 monthly principal payments 5 year term
  - Coupon = LIBOR + 6.25%; Floor of 8.35%















11

### **ESKATA – Practice Value Proposition**



Forecasting Tool*								
Input		Per Unit						
Unit Cost USD Unit Price USD	\$130.00 \$300.00	Gross Margin USE Gross Margin	) \$170.00 57%					
		Gross Profit						
Target Procedures	2	Daily	\$340.00					
Number of Locations	1	Weekly	\$1,700.00					
Number of Providers 1		Monthly	\$6,800.00					
* For illustration purposes only		Annually	\$89,080.00					

- Over 1,050 ESKATA accounts opened to date
- Sales force focused on driving clinical and business integration in existing accounts and expanding account base to support national DTC campaign
- Delegation to ancillary healthcare professional staff nurse, medical assistant, aesthetician
- Ability for practices to supplement incremental income

### U.S. Market Opportunity

### **83+MM** People in the US with SK<sup>1</sup>

18+MM visits to Derm for SK<sup>2</sup>

8+MM SK treatments<sup>2</sup>

#### Reasons for Not Removing SKs Include<sup>3</sup>:

- High risk of scarring
- High risk of hypopigmentation
- Want to avoid cutting, freezing or burning

### Opportunity to Engage Motivated Patients via DTC

In a survey of patients with SKs (n=406) who were evaluated by a dermatologist



Were extremely or somewhat interested **in paying out of pocket** to have their SKs removed if treatment were offered at a reasonable cost<sup>3</sup>



of **females** were so bothered by SK that they have tried to **hide**, **disguise** or **remove** their lesions on their own<sup>3</sup>



of **males** were so bothered by SK that they have tried to **hide**, **disguise** or **remove** their lesions on their own<sup>3</sup>

<sup>1</sup>Bickers et al. The Burden of Skin Disease. *J Am AcadDermatology*.2006;55:490-500. <sup>2</sup>Data on File. Aclaris Therapeutics, Inc. Burke Screener of 594 dermatologists. 2014. <sup>3</sup>Data on File. Aclaris Therapeutics, Inc. In-Office SK Treatment Study. Final Report. 2016.



### **ESKATA Consumer Initiatives**

**TV COMMERCIAL** 

STREAMING ONLINE:

network

You Tube

hulu HGTV

food

DIGITAL MEDIA & PARTNERSHIPS NEWBEAUTY reciself. marie claire ELLE WEBSITE PAGE TAKEOVERS CONDÉ NAST HEARST BEKATA.COM



MAGAZINE ADS

SOCIAL MEDIA


ienna

### A-101 45% Topical Solution Phase 3 Candidate For Common Warts




### Wart Market: Patient Visits by Wart Type

#### **Patient Visits for Warts**



### 4.1MM Patient Visits for Warts<sup>1</sup> Common Warts:

- 22MM prevalent population in the US<sup>2</sup>
- 2MM patient visits for common warts<sup>1</sup>
- 50% of all patient visits for warts<sup>1</sup>
- 3x more patient visits than genital warts<sup>1</sup>




<sup>2</sup> Nguyen et al, Laser Treatment of Nongenital Verrucae A Systematic Review, JAMA Dermatology. 2016;152(9):1025-1033

© Copyright 2019 Aclaris Therapeutics. All rights reserved



### **Common Warts: Patient Desire for Treatment**

- 50% of patients report moderate to extreme discomfort<sup>1</sup>
- 39% of patients say warts impact social/leisure activities<sup>1</sup>
- Perceived social stigma,<sup>2</sup> possibly due to contagious nature
- Warts can persist for years<sup>2</sup>
- OTC topical treatments containing salicylic acid are first-line and most common therapy that many patients choose<sup>1</sup>
  - Promote exfoliation; stimulate host immunity<sup>2</sup>
  - Slow to work; require frequent applications for up to 12 weeks<sup>2</sup>
  - Marginally effective; 1.6 times more likely to clear treated warts than placebo<sup>3</sup>



<sup>2</sup> Mulhem et al, Treatment of Nongenital Cutaneous Warts, American Family Physician; 84:3, 2011; 288-293.


<sup>3</sup> Sterling et al. British Association of Dermatologists' guidelines for the management of cutaneous warts 2014, British Journal of Dermatology; (2014) 171, 696–712.

<sup>4</sup> IMS National Disease and Therapeutic Index 2016

Caclaris.

<sup>&</sup>lt;sup>1</sup> Lipke M., An Armamentarium of Wart Treatments, *Clinical Medicine & Research*,4:4, 2006; 273–293.

### **Common Warts: Treatment Paradigm**



- Patient burden comes from the duration of treatment, time commitment, pain and discomfort, as well as the cost of treatments
- A-101 45% is viewed as less burdensome than many of the more aggressive in-office treatments as well as the OTC treatments that must be applied daily



18

Source: Burke Market Research, January 2016

### Summary of WART-203 Phase 2 Trial Results

Trial	Trial Design	Trial Outcome
WART–203 (N=159)	<ul> <li>A randomized, double-blind, vehicle-controlled, parallel-group study of A-101 45% solution in subjects with 1-6 common warts</li> <li>Self-treated twice weekly for a total of 16 treatments</li> </ul>	<ul> <li>Efficacy: Statistically significant results on all primary, secondary, and exploratory endpoints</li> <li>Favorable safety profile</li> </ul>

#### **Primary Endpoint:**

 Mean change from baseline in the Physician's Wart Assessment (PWA) score on target wart at day 56 (visit 10) using an analysis of covariance.

#### **Secondary Endpoints:**

- The proportion of subjects whose target wart is judged to be clear on the PWA at day 56.
- The proportion of subjects with all treated wart(s) clear, stratified by baseline number of warts at day 56.

#### **Exploratory Endpoints:**


• The percentage of all treated warts that were clear at day 56.

#### **Current Status**


• Initiated Phase 3 clinical trials September 2018.




# WART-203: The Percentage of All Treated Warts that are Clear on the PWA for Each Post-baseline Visit (N=159)



# WART-203: Proportion of Subjects Achieving Target Wart Clearance at each Post-Baseline Visit (N=159)



WART-203: Proportion of Subjects with all treated Wart(s) (1-6) Clear, Stratified by Baseline Number of Warts, at each Post-Baseline Visit (N=159)



© Copyright 2019 Aclaris Therapeutics. All rights reserved

### Core Intellectual Property: A-101

#### Issued US Patent # 7,381,427

- Directed to methods of treating/removing SK with high concentration hydrogen peroxide.
- Orange Book listed for ESKATA; estimated expiry date w/ potential PTE of 2<sup>1</sup>/<sub>2</sub> yrs ~ 2025.

#### Issued US Patent # 9,675,639

- Directed to topical compositions of high concentration hydrogen peroxide with 2-propanol, methods of use and applicators ~ total of 70 claims
- Orange Book listed for ESKATA; expires July 2035

#### • Issued US Patent # 9,980,983

- Directed to methods of treating/removing SK with 40% "stabilized" hydrogen peroxide ~ total of 25 claims
- Orange Book listed for ESKATA; expires April 2035

#### • Issued US Patent # 10,098,910

- Directed to an applicator containing a formulation of high concentration hydrogen peroxide and methods of using such an applicator to treat seborrheic keratosis (SK), warts and other indications ~ total of 18 claims
- Orange Book listed for ESKATA; expires April 2035

#### Pending Applications

- In US, directed to additional applicator and methods of treating warts with 45% hydrogen peroxide; subject matter of '639 and '983 Patents and foregoing also being pursued in major foreign markets; would expire in April 2035
- Directed to results of Aclaris Wart-201 Study data; would expire in August 2037.

#### Exclusive supply agreement with only cGMP manufacturer of Active Pharmaceutical Ingredient

- Exclusivity for 10 years from date of 1<sup>st</sup> commercial sale of product.
- Granted 3-year exclusivity, actively seeking 5-year exclusivity



### JAK Inhibitor Candidates



# ATI-501/ATI-502: Investigational Selective JAK 1/3 Inhibitors in Alopecia Areata, Vitiligo and Androgenetic Alopecia

#### **Portfolio and IP Estate:**

#### ATI-501 (oral) and ATI-502 (topical) – Selective JAK 1/3 inhibitor

### Additional topical JAK inhibitors in development

- Oral and topical rights
- Known MOA and observed biological response in humans
- Promoted hair regrowth in mouse model<sup>1</sup>
- Broad IP estate
- Know-how and methods of use covering JAK inhibitors for the treatment of:
  - Alopecia areata
  - Androgenetic alopecia (male and female pattern hair loss)
  - Additional hair loss disorders

### ATI-501 JAK1/JAK3

Oral treatment for alopecia totalis and alopecia universalis

### ATI-502 JAK1/JAK3

Topical treatment for patchy alopecia areata, androgenetic alopecia, and vitiligo

### **JAK1/JAK3** Inhibitor

"Soft Topical" treatment for atopic dermatitis, alopecia areata, and vitiligo



### Alopecia Areata (AA)


- 6.8+ million people in the U.S. have had or will develop AA during their lives<sup>1</sup>
  - 25-50% of patients have persistent patchy AA<sup>2</sup>
  - 14-25% of patients progress to alopecia totalis or universalis<sup>2</sup>
- AA is an autoimmune condition which ranges in severity:
  - Patchy Alopecia Areata patchy hair loss on scalp
  - Alopecia Totalis complete hair loss on scalp
  - Alopecia Universalis complete hair loss on scalp, face and body
- 2/3 of affected individuals <30 years old at disease onset<sup>3</sup>
- Translational research work by Dr. Angela Christiano at Columbia University






<sup>1</sup>National Alopecia Areata Foundation. hhttps://www.naaf.org/alopecia-areata. Last accessed July 2. 2019. <sup>2</sup>MacDonald, et al. Guidelines for the Management of Alopecia Areata. *Brit J Derm.* 2003 <sup>3</sup>Gilhar, A. et al. Alopecia Areata *NEJM* 366;16 nejm.org. 2012

### Mechanism of JAK Inhibitors in Alopecia



Divito & Kupper, Nature Medicine 20, 989-990 (2014).



HF of an AA patient

aclaris.

**Control Individual** 

Christiano Laboratory, Columbia University © Copyright 2019 Aclaris Therapeutics. All rights reserved

### Ruxolitinib and Tofacitinib in Alopecia Areata<sup>1</sup>

Baseline





RUXO - Baseline SALT 64%. Duration of hair loss 12 years. 6 months 20mg BID. Last SALT 1%

TOFA - Baseline SALT 100%, 5 months 5mg BID, 2 months 10/5 mg BID, 3 months 10mg BID ongoing. Last SALT 39%.

TOFA - Baseline SALT 84%, 6 months 5mg BID, 0 months 10/5mg, 0 months 10mg. Last SALT 0%.

TOFA - Baseline SALT 46%, 5 months at 5mg BID, 2 months at 10/5mg, 2 months 10mg ongoing. Last SALT 12%.



<sup>1</sup>Mackay-Wiggan, et al. JCI Insight. 2016 15:e89790. © Copyright 2019 Aclaris Therapeutics. All rights reserved

### Additional Potential Indications: Vitiligo

- Vitiligo is a common autoimmune disease where melanin (pigment) is absent, causing lighter patches of skin to appear on various parts of the body<sup>1,2</sup>
- Vitiligo impacts 0.5-2% of the global population irrespective of sex, race or age<sup>3</sup>
- Disease onset occurs in about onehalf of sufferers before the age of 20 years<sup>3</sup>
- Drug candidates: ATI-502 (topical) JAK inhibitors





#### <sup>1</sup> Roddick, J. Autoimmune Diseases. Healthline. 07.22.2015.


<sup>2</sup>Oakley, A. Vitiligo. DermnetNZ. 08.2015.

<sup>3</sup> Picardo\_2015\_Nature Reviews Disease Primers\_Vitiligo. © Copyright 2019 Aclaris Therapeutics. All rights reserved

### **Additional Potential Indications: AGA**

- Androgenetic alopecia (male/female pattern hair loss)
- AGA, a genetic disorder, is the most common cause of hair loss<sup>1</sup>
- Experienced by 70% of men and 40% of women at some point in their lives.<sup>1</sup> In 2012, 35 million men and 21 million women suffered hair loss<sup>2,3</sup>
- Sufferers are highly motivated to seek treatment<sup>1</sup>
- Drug candidate: Topical "Soft" JAK inhibitors in development





Cotsarelis , J Clin Invest. 2006;116(1):19-22.

<sup>1</sup> McElwee J., et al. Promising Therapies for Treating and/or Preventing Androgenic Alopecia. Medscape. 2012

- <sup>2</sup> International Society of Hair Restoration Surgery, http://www.ishrs.org/. Last accessed July 24, 2019.
- <sup>3</sup> Herskovitz, I, et al. Female Pattern Hair Loss. International Journal of Endocrinology and Metabolism. 2013 Oct; 11(4): e9860.

© Copyright 2019 Aclaris Therapeutics. All rights reserved

### Core Intellectual Property: JAK inhibitor

- US & Global JAK IP estate consisting of >150 patents/applications (issued and/or pending)
- Exclusive license with Rigel Pharmaceuticals for ATI-501 & ATI-502 (COM) in dermatology
  - US Natural expiry dates 2030-2034 + potential applicable PTE
  - Corresponding patents & applications in 18 additional jurisdictions (EU, AU, CA, IN, JP, others) -Natural expiry dates 2030 + potential applicable PTE
- Exclusive license under Columbia University
  - Covers the use of certain JAK inhibitors for the treatment of AA, AGA, and other hair loss disorders and biomarkers to identify potential responders
  - This portfolio includes a recently issued U.S. patent and recently allowed U.S. applications directed to methods of treating AA, AGA and other hair loss disorders by administering ruxolitinib, baricitinib, decernotinib, or tofacitinib, and a recently issued patent in Japan directed to pharmaceutical compositions comprising ruxolitinib, baricitinib, or tofacitinib for use in treating AA, AGA and other hair loss disorders
  - Natural expiry date 2031
  - Pending applications in Europe, Japan and Korea




## Inflammation and Immunology Platform



### Inflammation and Immunology

Walter Smith	Joseph Monahan, PhD	Jon Jacobsen, PhD	Paul Changelian, PhD			
Former VP Research & Global Head, Pfizer Inflammation, co-leader of Pfizer Licensing Team Delivered 8 clinical candidates, 6 INDs and 1 NDA in inflammation and cancer	Former Executive Director, Pfizer Inflammation Research and Leader of Global Kinase Technology Team >95 publications and patents (>30 total on kinases)	Former Research Fellow and Director, Pfizer Chemistry >100 publications and patents (15 total on kinases) Project Lead for PFE JAK Program	Immunologist/drug discovery leader at pharma (Pfizer) & biotech (Lycera, Infinity) Validated JAK 1/3 as target for transplant/RA/psoriasis, leading to approval of Xeljanz <sup>®</sup>			
PLATFORM	<ul> <li>Proprietary compound</li> <li>Medicinal chemistry, dis</li> </ul>	KINect™ platform – drug discovery engine Proprietary compound library and computational chemistry capability Medicinal chemistry, disease biology, immunology, pharmacology and preclinical development expertise				
PEOPLE	<ul><li>JAK inhibitors)</li><li>Kinome experts - chem discovery experience</li></ul>	Kinome experts - chemists and biologists; combined 300+ years of drug				
© Copyright 2019 Aclaris Therapeutics. All rights	s reserved		Caclaris 33			

### KINect Platform – Developing Better Kinase Drug Candidates Rapidly & Efficiently



more rapid target to candidate selection




in public domain and internal validation

### KINect<sup>™</sup> Discovery of Covalent Kinase Inhibitors

- Leverage interaction with cysteine free -SH to address issues of potency, selectivity and biochemical efficiency
- Precise placement of reactive group provides significant rate enhancement for covalent bond formation
- Maximizing reversible affinity and Minimizing reactivity to with the intent of developing efficacious and safe drugs





### **Research and Development Capabilities**

#### **BIOCHEMISTRY & ENZYMOLOGY**

- Leaders in Mechanistic Enzymology
- Custom Assay Development
- Compound: Target Interaction
- Enzyme Inhibitor Mechanisms
- Direct Binding Kinetics
- High Throughput Screening

#### **TRANSLATIONAL RESEARCH**

- Biomarker Assay Development
- Clinical Biomarker Assessment
- In vivo Efficacy and PK Studies
- PK/PD Relationship
- Release Assay Validation

#### **BIOANALYTICAL CHEMISTRY**

- Non-GLP Analytical
- Bioanalytical Method Development
- Bioanalytical Method Validation
- Pharmacokinetic/Toxicokinetic Analysis
- Ab Solubility and Aggregation

#### **CELL & MOLECULAR BIOLOGY**

- Target Clone/Express/Purification
- Translatable Cellular Assays
- Target Modulation/Disease Assays
- Cell Pathway Interrogation
- Custom Assay Development
- Multiple Assay Platforms

#### IMMUNOLOGY & IMMUNO-ONCOLOGY

- Cytokine Expression
- Th Cell Differentiation/Activation
- CTL Differentiation and Function
- B Cell and NK cell Function
- Ag Specific Cell and In Vivo Models
- HWB/PBMC/Monocyte Assays

#### **COMPUTATIONAL & MEDICINAL CHEMISTRY**

- Schrödinger ™ Enabled Structure Based Drug Design
- Computational Chemistry
- Library Design
- Compound Synthesis



### The Kinase Opportunity: Rational Targeted Drug Discovery

### Creating New Medicines Targeting Previously Inaccessible Parts of the Kinome

#### KINect<sup>™</sup> Technology Platform

#### Proprietary chemical library and integrated capabilities for interrogating the Kinome

- Solves challenges encountered in the class
  - Selectivity
  - Biochemical efficiency
- Validity of targeting kinases is commercially established
- Plethora of validated kinase targets are inadequately drugged
- KINect<sup>™</sup> platform allows rational targeting of validated kinase targets

#### Kinase Drugs Represented \$240B in Aggregate Global Sales from 2011-2015<sup>1</sup>




#### 500 member class, representing 2% of the human genome



<sup>1</sup> <u>https://www.nature.com/nrd/posters/druggablegenome/nrd\_druggablegenome.pdf</u>. Last Accessed 8-2-18 © Copyright 2019 Aclaris Therapeutics. All rights reserved

### MK-2 Inhibitor: Inflammatory Cytokines Drive Disease Pathophysiology




Anti-TNF Biologic Drugs: Humira<sup>®</sup>, Enbrel<sup>®</sup>, Remicade<sup>®</sup> (>\$30B sales) Anti IL-1 Biologic Drugs: Kineret<sup>®</sup>, Ilaris<sup>®</sup>, Arcalyst<sup>®</sup> (~\$1B Sales)

Strategy: develop an oral drug with efficacy paralleling anti-TNF and anti-IL1 biologics



### Challenge of Traditional p38 Inhibitors Transient Efficacy or Tachyphylaxis

### Tachyphylaxis: Rheumatoid Arthritis Study\*




#### JNJ/SCIO-469 CRP Levels

\*Genovese, et al., J Rheumatology (2011)

- Safety Transient ↑ LFT, Rash
- Transient Efficacy No Go for RA
- Also seen in IBD, ACS

#### Hypothesis:

- Global p38 inhibition blocks inflammatory and anti-inflammatory pathways
- MK2 pathway inhibitor is expected to maintain efficacy through selective inhibition of the inflammatory pathways




Schematic of MK2 dependent inflammatory pathway and other anti-inflammatory pathways downstream of p38MAPK



### Mouse LPS-Induced TNFa Production ATI-450 demonstrated durable response (no tachyphylaxis)

- Global p38 inhibitor CDD-111 lost efficacy as a function of dosing duration over 4 weeks
- This lack of durable efficacy was similar to that observed in IBD and RA clinical studies with global p38 inhibitors
- This investigational MK2 pathway inhibitor ATI-450 demonstrated durable responses in this model (no tachyphylaxis)




- Conventional p38 (CDD-111) and MK2PI (ATI-450) administered to mice in feed starting day 1 and continuing through day 28
- At the time point indicated, mice were LPS challenged and blood TNF $\alpha$  levels determined




### In vivo Results of MK2 Pathway Inhibitor ATI-450

#### Joint Protection in Rat Arthritis Model<sup>1</sup>



Cytokine Modulation in Orphan Autoinflammatory Disease (CAPS)<sup>1</sup>




Blockade of Gut Inflammatory Infiltrate in Murine Adoptive Transfer Ulcerative Colitis Model<sup>3</sup>



Reduction in Breast Cancer Bone Metastasis in Mice<sup>2</sup>

#### **Bone Metastasis**




Caclaris.

<sup>1</sup> Wang C, et al. J Exp Med. 2019;215(5):1315-1325. <sup>2</sup> Murali B, et al. Cancer Res. 2019;78(19)5618-5630. <sup>3</sup> Data on File. Aclaris Therapeutics Inc.

### ATI-1777: Soft Topical JAK1/3 Drug Candidate Preclinical Results

- ATI-1777 demonstrated low nM potency against JAK1 and JAK3 enzymes and cellular assays
- Good skin penetration and topical anti-inflammatory effect observed
- Rapidly metabolized and cleared by the liver from blood plasma
- Clean in CEREP pharmacology panel, high kinome selectivity, negative in Ames and high margin in hERG and rat IVT


#### **Topical pSTAT3 Mouse Model<sup>1</sup>**





### ITK/JAK3 Inhibitors as Anti-Inflammatory Drug Candidates

- Autoimmune diseases are driven by both T cell and cytokine receptors
- Inhibitors of ITK act as small molecule inhibitors of Th17 and Th1 cells, primary drivers of autoimmune disease
- JAK3 regulates IL-2, IL-4 and IL15, three cytokines that drive autoimmune diseases in general, but dermatological diseases in particular
- Aclaris has generated covalent ITK/JAK3 drug candidates specifically designed for oral delivery or as soft topical drugs for potential treatment of autoimmune disease



#### ITK Regulates the T Cell Receptor<sup>1</sup>



<sup>1</sup> Andreotti, et al. *Cold Spring Harb Perspect Biol 2010;2:*a002287 <sup>2</sup> Marcais, et al. *Frontiers in Immunology*. 2013;4:1-14. © Copyright 2019 Aclaris Therapeutics. All rights reserved

### Fully Integrated Biopharmaceutical Company



## THANK YOU

